Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in... see more

TSXV:BTI.H - Post Discussion

View:
Post by frogman on Dec 11, 2020 10:31am

Dr Rathjen cv

for your info........

Deborah Ann Rathjen – Executive Chair, President & Chief Executive Officer
 
Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE, is the Chief Executive Officer and Executive Chair at Bioasis Technologies Inc. Prior to joining the Corporation, Dr. Rathjen was the Chief Executive Officer and Managing Director of Bionomics Limited, having joined Bionomics Limited, a public Australian biotechnology company engaged in the research and development of new therapies for brain disorders and cancer, in 2000 from Peptech Limited (now owned by Teva), where she was General Manager of Business Development and Licensing. She was a co-inventor of Peptech Limited’s TNF technology, which underpins the products Humira and Remicade used in the treatment of autoimmune disorders, and leader of the company’s successful defense of its key TNF patents against a legal challenge by BASF and Johnson and Johnson (J&J).
 
Dr. Rathjen has significant experience in company building and financing, mergers and acquisitions, therapeutic product research and development, business development, licensing and commercialization and has achieved in excess of $900 million in deals including  6 partnerships with Merck & Co., J&J, Abbott (AbbVie), Nycomed (Takeda), Chiesi Group and Merck KGaA. Dr. Rathjen has raised over $200 million in biotech company financings. Dr. Rathjen has been recognized internationally with awards and honors including the 2004 AusBiotech President’s Medal, 2006 Flinders University Distinguished Alumni Award, 2009 BioSingapore Asia Pacific Biotechnology Woman Entrepreneur of the Year, 2009 Regional Finalist Ernst & Young – Entrepreneur of the Year and 2014 Woman Executive of the Year BioPharm Industry Awards. In 2015 Dr. Rathjen was included in the top 50 most influential Australian businesswomen by The Australian newspaper.
 
Dr. Rathjen received her doctor of philosophy degree in immunology from Macquarie University in Sydney, Australia, and her bachelor of science degree, with honours, in immunology from Flinders University in Adelaide, Australia.
 
Comment by narmac on Dec 11, 2020 11:30am
,,DNLI,,,Denali made another 52 week high today,,market cap 9.6 Billion USD. Speaks well for us down the road here. Bring it on DrDR!!!!!
Comment by G1945V on Dec 11, 2020 2:04pm
BTW, in the Q&A, Mario Saltarelli suggests that Bioasis should at least be able to achieve what Denali is doing.  Remains to be seen. G1945V 
Comment by regardless on Dec 11, 2020 2:14pm
Yet they keep comparing us to them lol 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities